| Name | Title | Contact Details |
|---|
We are the nation`s largest veterinary partner-pharmacy providing veterinarians with a custom online store so they can offer the best home delivery service for their clients. We offer pet owners a way to shop online with their own veterinarian in a safe and secure web store for their pet. Behind the scenes, we are the veterinarian`s fully-licensed and accredited veterinary pharmacy. We have direct partnerships with all of the manufacturers--so we don`t just guarantee that the products “are the same”...we 100% guarantee that all products have been handled properly to maintain their quality. That`s a big difference when it comes to the safety of a pet.
Stream Pickett is a Decatur, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mindleap is an advanced digital health platform that helps people connect with mental health specialists that can empower them to thrive and develop habits for a healthy mind. Online mental healthcare brings convenience, improves access to treatments and can lead to more personal breakthroughs. Mindleap`s proprietary platform is designed by clinical psychologists and neuroscientists to provide professional support and personalized treatment for every person.
Provation is a leading provider of clinical productivity software for healthcare professionals, with solutions for intelligent procedure documentation (Provation® MD and Provation® Apex), order set and care plan management (Provation® Order Sets and Provation® Care Plans), and EHR-embedded clinical documentation templates (Provation® Clinic Note). Our software helps providers increase operational efficiencies, business profitability and regulatory compliance by improving quality, streamlining workflows and enabling the generation of insights. Trusted by leading physicians globally, we serve approximately 1,500 hospitals and 1,000 ambulatory surgery centers (ASCs), including 16 of the top 20 U.S. hospitals for gastroenterology (GI) and GI surgery. Provation is headquartered in Minneapolis, MN and is owned by Clearlake Capital Group, L.P.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic